Semi-physiologically based pharmacokinetic modeling of paclitaxel metabolism and in silico-based study of the dynamic sensitivities in pathway kinetics

European Journal of Pharmaceutical Sciences

Volumn 47, Issue 4, 2012, Pages 759-767

  Fransson, Martin N ^a   Brugård, Jan ^b   Aronsson, Peter ^b   Gréen, Henrik ^c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MathCore Engineering AB   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

CYP2C8; CYP3A4; Mathematical modeling; Paclitaxel metabolism; Pharmacokinetics; Sensitivity analysis

Indexed keywords

CREMOPHOR; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DRUG METABOLITE; PACLITAXEL;

ARTICLE; COMPUTER MODEL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG UPTAKE; GENETIC POLYMORPHISM; MATHEMATICAL MODEL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COMPUTER SIMULATION; HEPATOCYTES; HUMANS; KINETICS; LIVER; MODELS, BIOLOGICAL; PACLITAXEL;

EID: 84866479269     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.08.002     Document Type: Article

References (42)

1. L. Aarons Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed Br. J. Clin. Pharmacol. 60 2005 581 583
2. Z.E. Barter, M.K. Bayliss, P.H. Beaune, A.R. Boobis, D.J. Carlile, R.J. Edwards, J.B. Houston, B.G. Lake, J.C. Lipscomb, O.R. Pelkonen, G.T. Tucker, and A. Rostami-Hodjegan Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver Curr. Drug Metab. 8 2007 33 45
3. K. Bartholome, M. Rius, K. Letschert, D. Keller, J. Timmer, and D. Keppler Data-based mathematical modeling of vectorial transport across double-transfected polarized cells Drug Metab. Dispos. 35 2007 1476 1481
4. T.K. Bergmann, C. Brasch-Andersen, H. Green, M. Mirza, R.S. Pedersen, F. Nielsen, K. Skougaard, J. Wihl, N. Keldsen, P. Damkier, L.E. Friberg, C. Peterson, W. Vach, M.O. Karlsson, and K. Brosen Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer Pharmacogenom. J. 11 2011 113 120
5. T. Cresteil, B. Monsarrat, P. Alvinerie, J.M. Treluyer, I. Vieira, and M. Wright Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation Cancer Res. 54 1994 386 392
6. T. Cresteil, B. Monsarrat, J. Dubois, M. Sonnier, P. Alvinerie, and F. Gueritte Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship Drug Metab. Dispos. 30 2002 438 445
7. M. Czejka, J. Schueller, H. Schnait, B. Springer, and I. Eder Clinical pharmacokinetics and metabolism of paclitaxel after a 3-h infusion: comparison of two preparations J. Oncol. Pharm. Pract. 9 2003 129 136
8. G.L. de la Grandmaison, I. Clairand, and M. Durigon Organ weight in 684 adult autopsies: new tables for a Caucasoid population Forensic Sci. Int. 119 2001 149 154
9. M.N. Fransson, H. Green, J.E. Litton, and L.E. Friberg Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model Drug Metab. Dispos. 39 2011 247 255
10. E.M. Geraghty, J.M. Boone, J.P. McGahan, and K. Jain Normal organ volume assessment from abdominal CT Abdom Imag. 29 2004 482 490
11. H. Green, P. Soderkvist, P. Rosenberg, R.A. Mirghani, P. Rymark, E.A. Lundqvist, and C. Peterson Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer Basic Clin. Pharmacol. Toxicol. 104 2009 130 137
12. J.W. Harris, A. Katki, L.W. Anderson, G.N. Chmurny, J.V. Paukstelis, and J.M. Collins Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol J. Med. Chem. 37 1994 706 709
13. J.W. Harris, A. Rahman, B.R. Kim, F.P. Guengerich, and J.M. Collins Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme Cancer Res. 54 1994 4026 4035
14. A. Henningsson, M.O. Karlsson, L. Vigano, L. Gianni, J. Verweij, and A. Sparreboom Mechanism-based pharmacokinetic model for paclitaxel J. Clin. Oncol. 19 2001 4065 4073
15. A. Henningsson, A. Sparreboom, M. Sandstrom, A. Freijs, R. Larsson, J. Bergh, P. Nygren, and M.O. Karlsson Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients Eur. J. Cancer 39 2003 1105 1114
16. A. Henningsson, S. Marsh, W.J. Loos, M.O. Karlsson, A. Garsa, K. Mross, S. Mielke, L. Vigano, A. Locatelli, J. Verweij, A. Sparreboom, and H.L. McLeod Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel Clin. Cancer Res. 11 2005 8097 8104
17. Henningsson, A., Sparreboom, A., Loos, W.J., Verweij, J., Silvander, M., Karlsson, M.O., 2005b. Population pharmacokinetic model for Cremophor EL (Abstract). pp. 14, 770.
18. A.C. Hindmarsh, P.N. Brown, K.E. Grant, S.L. Lee, R. Serban, D.E. Shumaker, and C.S. Woodward SUNDIALS: suite of nonlinear and differential/algebraic equation solvers ACM Trans. Math. Softw. 31 2005 363 396
19. P.J. Hurley Red cell and plasma volumes in normal adults J. Nucl. Med. 16 1975 46 52
20. S.H. Jang, M.G. Wientjes, and J.L. Au Kinetics of P-glycoprotein-mediated efflux of paclitaxel J. Pharmacol. Exp. Ther. 298 2001 1236 1242
21. M. Joerger, A.D. Huitema, D.H. van den Bongard, J.H. Schellens, and J.H. Beijnen Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors Clin. Cancer Res. 12 2006 2150 2157
22. M.O. Karlsson, V. Molnar, A. Freijs, P. Nygren, J. Bergh, and R. Larsson Pharmacokinetic models for the saturable distribution of paclitaxel Drug Metab. Dispos. 27 1999 1220 1223
23. M. Kato, K. Chiba, T. Ito, T. Koue, and Y. Sugiyama Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans Drug Metab. Pharmacokinet. 25 2010 367 378
24. H.J. Kuh, S.H. Jang, M.G. Wientjes, and J.L. Au Computational model of intracellular pharmacokinetics of paclitaxel J. Pharmacol. Exp. Ther. 293 2000 761 770
25. G.N. Kumar, J.E. Oatis, K.R. Thornburg, F.J. Heldrich, E.S. Hazard, and T. Walle 6 alpha-Hydroxytaxol: isolation and identification of the major metabolite of taxol in human liver microsomes Drug Metab. Dispos. 22 1994 177 179
26. S. Leskela, C. Jara, L.J. Leandro-Garcia, A. Martinez, J. Garcia-Donas, S. Hernando, A. Hurtado, J.C. Vicario, C. Montero-Conde, I. Landa, E. Lopez-Jimenez, A. Cascon, R.L. Milne, M. Robledo, and C. Rodriguez-Antona Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity Pharmacogenom. J. 11 2011 121 129
27. G. Molino, P. Avagnina, M. Ballare, M. Torchio, A.G. Niro, P.E. Aurucci, M. Grosso, and C. Fava Combined evaluation of total and functional liver plasma flows and intrahepatic shunting Dig. Dis. Sci. 36 1991 1189 1196
28. B. Monsarrat, P. Alvinerie, M. Wright, J. Dubois, F. Gueritte-Voegelein, D. Guenard, R.C. Donehower, and E.K. Rowinsky Hepatic metabolism and biliary excretion of Taxol in rats and humans J. Natl. Cancer Inst. Monogr. 1993 39 46
29. M. Nakajima, Y. Fujiki, S. Kyo, T. Kanaya, M. Nakamura, Y. Maida, M. Tanaka, M. Inoue, and T. Yokoi Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 J. Clin. Pharmacol. 45 2005 674 682
30. S.B. Naraharisetti, Y.S. Lin, M.J. Rieder, K.D. Marciante, B.M. Psaty, K.E. Thummel, and R.A. Totah Human liver expression of CYP2C8: gender, age, and genotype effects Drug Metab. Dispos. 38 2010 889 893
31. A. Rahman, K.R. Korzekwa, J. Grogan, F.J. Gonzalez, and J.W. Harris Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8 Cancer Res. 54 1994 5543 5546
32. G.L. Sirianni, and K.S. Pang Organ clearance concepts: new perspectives on old principles J. Pharmacokinet. Biopharm. 25 1997 449 470
33. N.F. Smith, M.R. Acharya, N. Desai, W.D. Figg, and A. Sparreboom Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel Cancer Biol. Ther. 4 2005 815 818
34. D.S. Sonnichsen, Q. Liu, E.G. Schuetz, J.D. Schuetz, A. Pappo, and M.V. Relling Variability in human cytochrome P450 paclitaxel metabolism J. Pharmacol. Exp. Ther. 275 1995 566 575
35. A. Sparreboom, and W.D. Figg Identifying sources of interindividual pharmacokinetic variability with population modeling Clin. Cancer Res. 12 2006 1951 1953
36. A. Sparreboom, O. van Tellingen, W.J. Nooijen, and J.H. Beijnen Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL Cancer Res. 56 1996 2112 2115
37. H. Taniguchi, M. Masuyama, H. Koyama, A. Oguro, and T. Takahashi Quantitative measurement of human tissue hepatic blood volume by C15O inhalation with positron-emission tomography Liver 16 1996 258 262
38. S.D. Undevia, G. Gomez-Abuin, and M.J. Ratain Pharmacokinetic variability of anticancer agents Nat. Rev. Cancer 5 2005 447 458
39. A. Varma, M. Morbidelli, and H. Wu Parametric Sensitivity in Chemical Systems. Cambridge Series in Chemical Engineering 1999 Cambridge University Press
40. T. Walle, U.K. Walle, G.N. Kumar, and K.N. Bhalla Taxol metabolism and disposition in cancer patients Drug Metab. Dispos. 23 1995 506 512
41. W.H. Wu, F.S. Wang, and M.S. Chang Dynamic sensitivity analysis of biological systems BMC Bioinform. 12 9 Suppl. 2008 S17
42. H. Yamaguchi, T. Hishinuma, N. Endo, H. Tsukamoto, Y. Kishikawa, M. Sato, Y. Murai, M. Hiratsuka, K. Ito, C. Okamura, N. Yaegashi, N. Suzuki, Y. Tomioka, and J. Goto Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer Int. J. Gynecol. Cancer 16 2006 979 985